Chiara Botto
Chiara Botto has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gaetano Giammona
Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy
3 shared publications - Maria Luisa Bondì
Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
3 shared publications - Antonina Azzolina
Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy, Consiglio Nazionale delle Ricerche, Via Ugo la Malfa 153, 90146 Palermo, Italy
2 shared publications - Emanuela Fabiola Craparo
Lab of Biocompatible Polymers, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, Palermo 90123, Italy
2 shared publications - Erika Amore
Istituto per lo Studio dei Materiali Nanostrutturati, U.O.S. Palermo, Consiglio Nazionale delle Ricerche, Via Ugo la Malfa 153, 90146 Palermo, Italy
2 shared publications - Melchiorre Cervello
Institute of Biomedicine and Molecular Immunology Alberto Monroy, National Research Council (CNR), Palermo, Italy
2 shared publications
Latest Publications
- Open Access
- 13 January 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 3
Correction to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
Following publication of our article [1], we became aware that Roberto Di Gesù had been omitted from the list of authors. The corrected author list and authors’ contribution statement appear below. We apologize for any inconvenience this may have caused.
- 13 January 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 3
Open AccessCorrection to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
Following publication of our article [1], we became aware that Roberto Di Gesù had been omitted from the list of authors. The corrected author list and authors’ contribution statement appear below. We apologize for any inconvenience this may have caused.
- Open Access
- 29 November 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 46
Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers
Nanomedicine studies have showed a great potential for drug delivery into the lung. In this manuscript nanostructured lipid carriers (NLC) containing Fluticasone propionate (FP) were prepared and their biocompatibility and effects in a human bronchial epithelial cell line (16-HBE) stimulated with cigarette smoke extracts (CSE) were tested. Biocompatibility studies showed that the NLC did not induce cell necrosis or apoptosis. Moreover, it was confirmed that CSE increased intracellular ROS production and TLR4 expression in bronchial epithelial cells and that FP-loaded NLC were more effective than free drug in modulating these processes. Finally, the nanoparticles increased GSH levels improving cell protection against oxidative stress. The present study shows that NLC may be considered a promising strategy to improve corticosteroid mediated effects in cellular models associated to corticosteroid resistance. The NLC containing FP can be considered good systems for dosage forms useful for increasing the effectiveness of fluticasone decreasing its side effects.
- 29 November 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 46
Open AccessEffects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers
Nanomedicine studies have showed a great potential for drug delivery into the lung. In this manuscript nanostructured lipid carriers (NLC) containing Fluticasone propionate (FP) were prepared and their biocompatibility and effects in a human bronchial epithelial cell line (16-HBE) stimulated with cigarette smoke extracts (CSE) were tested. Biocompatibility studies showed that the NLC did not induce cell necrosis or apoptosis. Moreover, it was confirmed that CSE increased intracellular ROS production and TLR4 expression in bronchial epithelial cells and that FP-loaded NLC were more effective than free drug in modulating these processes. Finally, the nanoparticles increased GSH levels improving cell protection against oxidative stress. The present study shows that NLC may be considered a promising strategy to improve corticosteroid mediated effects in cellular models associated to corticosteroid resistance. The NLC containing FP can be considered good systems for dosage forms useful for increasing the effectiveness of fluticasone decreasing its side effects.
- Open Access
- 1 January 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 21
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery.
- 1 January 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 21
Open AccessEntrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery.